Skip to main content

Table 1 Patients’ characteristics

From: Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1

Parameter

 

Patients, n

88

Gender, n (%)

Male

Female

64 (73)

24 (27)

Age at diagnosis, median, years (range)

Age at bortezomib start, median, years (range)

61 (30–79)

62 (30–79)

Subtype, n (%)

IgG

Non-IgG

LC

46 (52)

18 (21)

24 (27)

Cytogenetics, n (%)

High-risk#

Standard-risk

18 (20)

70 (80)

Patient groups, n (%)

Bortezomib naïve

under ongoing bortezomib treatment

s.p. bortezomib treatment§

10 (11)

37 (42)

41 (47)

Prior treatment, n (%)

Immunomodulatory drugs

Lenalidomide

Pomalidomide

Thalidomide

Proteasome inhibitors other than bortezomib

Carfilzomib

Ixazomib

Monoclonal antibodies

Daratumumab

Elotuzumab

48 (55)

26 (30)

27 (31)

22 (25)

5 (6)

65 (74)

9 (10)

Pre-existing peripheral neuropathy, n (%)

Idiopathic sensory-motor polyneuropathy

Diabetic neuropathy

Sensory-motor deficits after intracranial hemorrhage

3 (3)

1 (1)

1 (1)

Prevalence of BIPN, n (%)

No BIPN

BIPN without pain

Painful BIPN

15 (17)

39 (44)

34 (39)

BIPN grade, n (%)

No BIPN

Grade 1

Grade 2

Grade 3

15 (17)

44 (50)

26 (30)

3 (3)

  1. BIPN - bortezomib induced peripheral neuropathy; LC - light chain; # defined as presence of at least one of the following: t(4;14), t(14;16), t(14;20), del(17p). § Bortezomib had been given but was already stopped prior to the inclusion in the current study